We expect to report additional data from monotherapy expansion cohorts later in 2021. 2 Our pipeline The following chart summarizes our clinical product pipeline. The PFS observed to date in many 4 other solid tumor types has been more limited. This patient reported decreased swelling and noted improved mobility of his arm. As of July 7, 2020, dosing was continuing in this patient. This interaction acts to inhibit the antitumor activity of effector T cells and NK cells. Affinity was not assessed on other immune cells that express TIGIT. This family is a provisional application, filed March 5, 2021. We have two patent families directed to our anti-TIGIT antibody program. The statutory expiration for any patent issuing from this family will be January 7, 2040. Some long-term preclinical testing may continue after the IND is submitted. Also, some types of studies are exempt from the IDE regulations. This final rule codified CMS's policy change that was effective January 1, 2019. A separate application will, however, still be required. The risks and uncertainties described below are not the only ones we face. We also plan to evaluate inupadenant in a third part with carboplatin and paclitaxel. We are currently focusing on the development of inupadenant and EOS-448. Additionally, the process of finding patients may prove costly. Carrying out pivotal clinical trials is a complicated process. Any such restrictions could limit sales of the product. Orphan drug designation must be requested before submitting an NDA or BLA. In addition, the FDA may withdraw any Fast Track designation at any time.& & We may not be successful in such a transition. We are still in the early stages of development of our product candidates. As of December 31, 2020, we had an accumulated deficit of $73.9 million. We have never generated any revenue from product sales and may never be profitable. A patent term extension based on regulatory delay may be available in the United States. Further measures may be taken as the pandemic continues. These measures could negatively affect our business. The excess portion may be refunded as from the end of a five-year fiscal period. This is referred to as the fixed repayment.